

Supplemental Digital Content 11

Seroprotection rate and seroconversion rate for HI antibodies 7 days after first vaccination in the revaccination study (per-protocol cohort excluding children with an RT-PCR-confirmed influenza infection in the primary study)

	Primed			Unprimed		
	N	n	Rate, % (95% CI)	N	n	Rate, % (95% CI)
SPR						
A/H1N1	213	206	96.7 (93.3-98.7)	179	59	33.0 (26.1-40.4)
A/H3N2	213	182	85.4 (80.0-89.9)	179	54	30.2 (23.5-37.5)
B/Victoria	213	206	96.7 (93.3-98.7)	179	70	39.1 (31.9-46.7)
B/Yamagata	213	205	96.2 (92.7-98.4)	179	70	39.1 (31.9-46.7)
SCR						
A/H1N1	210	160	76.2 (69.8-81.8)	173	54	31.2 (24.4-38.7)
A/H3N2	210	173	82.4 (76.5-87.3)	173	49	28.3 (21.7-35.7)
B/Victoria	210	162	77.1 (70.9-82.6)	173	66	38.2 (30.9-45.8)
B/Yamagata	210	197	93.8 (89.6-96.7)	173	65	37.6 (30.3-45.2)

CI: confidence interval; HI: hemagglutination inhibition; RT-PCR: reverse transcription polymerase chain reaction; SCR: seroconversion rate; SPR: seroprotection rate